Radiation therapy for increasing prostate-specific antigen levels after radical prostatectomy

Clinical Prostate Cancer

Volumn 1, Issue 4, 2003, Pages 235-241

  Perez, Carlos A ^c   Michalski, Jeff M ^c   Baglan, Kathy ^a   Andriole, Gerald ^b   Cui, Qi ^c   Lockett, Mary Ann ^c  

^a ST JOHN S MERCY MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Radiation Oncology ^*

Author keywords

Biochemical failure; Disease free survival; Irradiation; Metastases

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; DRUG TOLERABILITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POSTOPERATIVE CARE; PROBABILITY; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE DIAGNOSIS; RADIATION DOSE; RADIATION INJURY; SCORING SYSTEM;

EID: 0041970168     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2003.n.005     Document Type: Article

References (35)

1. Lu-Yao GL, McLarran D, Wasson JH, et al. An assessment of radical prostatectomy: time trends, geographic variation, and outcomes. JAMA 1993; 269:2633-2636.
2. Pound CR, Partin AW, Epstein JH, et al. Prostate-specific antigen after radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24:395-406.
3. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152:1837-1842.
4. Ohori M, Goad JR, Wheeler TM, et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152:1843-1849.
5. Valicenti RK, Gomella LG, Ismail M, et al. Effect of higher radiation dose on biochemical control after radical prostatectomy for pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 1998; 42:501-506.
6. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys 2000; 48:369-375.
7. Keisch ME, Perez CA, Grigsby PW, et al. Preliminary report on 10 patients treated by irradiation after radical prostatectomy for isolated elevation of serum PSA levels. Int J Radiat Oncol Biol Phys 1990; 19:1503-1506.
8. Perez CA, Eisbruch A. Role of postradical prostatectomy irradiation in carcinoma of the prostate. Semin Radiat Oncol 1993; 3:198-209.
9. International Commission on Radiation Units and Measurements: Report No. 50: Prescribing, recording, and reporting photon beam therapy. Washington, D.C. ICRU, 1993.
10. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chron Dis 1958; 8:699-713.
11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170.
12. Pearson ES, Hartley HO. Biometrika tables for statisticians. Vol 1. 3rd ed. Cambridge, England: Cambridge University Press; 1966.
13. Partin AW, Pound C, Clemons J, et al. Serum PSA after anatomic radical prostatectomy: The John Hopkins experience after 10 years. Urol Clin North Am 1993; 20:713-725.
14. Prestidge B, Kaplan I, Cox RS, et al. Predictors of survival after a positive post-irradiation prostate biopsy. Int J Radiat Oncol Biol Phys 1994; 28:17-22.
15. Jhaveri FM, Klein EA. How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure. Semin Urol Oncol 1999; 17:130-134.
16. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145:907-923.
17. Patel A, Dorey F, Franklin J, et al. Recurrence patterns after radical prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158:1441-1445.
18. Sodee DB, Malguria N, Faulhaber P, et al. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. Urology 2000; 56:988-993.
19. Ruffion A, Valignat C, Champetier D, et al. Observation/delayed treatment for rising PSA after radical prostatectomy: Pros and cons. Semin Radiat Oncol 1999; 17:135-140.
20. Link P, Freiha FS, Stamey TA. Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol 1991; 145:532-534.
21. Schild SE. Radiation therapy after prostatectomy: now or later? Semin Radiat Oncol 1998; 8:132-139.
22. McCarthy JF, Catalona WJ, Hudson MA. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J Urol 1994; 151:1575-1578.
23. Forman JD, Meetze K, Pontes E, et al. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate-specific antigen level. J Urol 1997; 158:1436-1440.
24. Garg MK, Tekyi-Mensah S, Bolton S, et al. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 1998; 51:998-1002.
25. Vicini FA, Ziaja EL, Kestin LL, et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 1999; 54:111-117.
26. Cadeddu JA, Partin AW, DeWeese TL, et al. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998; 159:173-178.
27. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-1597.
28. Perez CA, Michalski J, Brown KC, et al. Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1996; 36:573-584.
29. Seaward SA, Weinberg V, Lewis P, et al. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 1998; 42:1055-1062.
30. Zelefsky MJ, Aschkenasy E, Kelsen S, et al. Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1997; 39:327-333.
31. Katz MS, Zelefsky MJ, Venkatraman ES, et al. Risk stratification predicts biochemical outcome after salvage post-prostatectomy three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2001; 51(suppl 1):170.
32. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol 1999; 17:1155.
33. D'Amico AV, Whittington R, Malkowicz SB, et al. An analysis of the time course of post-operative prostate-specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy. Urology 1996; 47:538-547.
34. Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTXN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 1998; 159:357-364.
35. Radiation Therapy Oncology Group Protocol 96-01: A phase III trial of radiation therapy with or without Casodex in patients with PSA elevation following radical prostatectomy for pT3N0 carcinoma of the prostate. Study Chairs: William U. Shipley, Derek Raghavan, Niall M. Heney, David Grignon.